Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Everolimus Overview

Everolimus is the 40-O-(2-hydroxyethyl) derivative of sirolimus and works similarly to sirolimus as an inhibitor of mammalian target of rapamycin (mTOR). It is currently used as an immunosuppressant to prevent rejection of organ transplants and in the treatment of renal cell cancer and other tumours. Much research has also been conducted on everolimus and other mTOR inhibitors as targeted therapy for use in a number of cancers. It is marketed by Novartis under the trade names Zortress (USA) ...

Read more Everolimus Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Everolimus

Recent Everolimus Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Suspension: 2mg, 3mg, 5mg
  • Tablet: 0.25mg, 0.5mg, 0.75mg, 10mg, 1mg, 2.5mg, 5mg, 7.5mg
  • Tablet, For Suspension: 2mg, 3mg, 5mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Everolimus: (3 results)

Sorted by National Drug Code
  • 49884-119 Everolimus 2.5 mg Oral Tablet by Par Pharmaceutical, Inc.
  • 49884-125 Everolimus 5 mg Oral Tablet by Par Pharmaceutical, Inc.
  • 49884-127 Everolimus 7.5 mg Oral Tablet by Par Pharmaceutical, Inc.

Other drugs which contain Everolimus or a similar ingredient: (4 results)

Related Everolimus Topics:

Everolimus Face Rash
Side Effects of Everolimus including face and body rash; swollen feet...
Everolimus Side Effects
Everolimus Side Effects: Face and Body Rash...

Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 8 April 2020.

We are committed to your privacy.

Copyright © 2005-2020 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA